FDA Generic Office Director Uhl Returns From Medical Leave
This article was originally published in The Pink Sheet Daily
Executive Summary
Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.
You may also be interested in...
Generics Office At US FDA Could Get New Director Before Uhl Departs
Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.
US FDA Generic Drug Office Director Uhl Announces Retirement
Uhl, who shepherded OGD into the user fee era, will retire in February.
US FDA Generic Drug Office Director Uhl Announces Retirement
Uhl, who shepherded OGD into the user fee era, will retire in February.